Articles by E. David Crawford, MD
In the final episode, “Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer,” the panelists explored the evolving role of treatment intensification strategies for patients with metastatic castration-sensitive prostate cancer (mCSPC). Using the case of a 63-year-old man with de novo high-volume metastatic disease, the expert faculty discussed how disease burden, patient fitness, comorbidities, and individual treatment goals influence decisions regarding doublet versus triplet therapy.
In “Managing High-Risk Biochemical Recurrence in Advanced Prostate Cancer,” our panel explores the evolving treatment landscape for patients experiencing biochemical recurrence following definitive therapy. Through the case of a 75-year-old man with a rising PSA after radical prostatectomy, a rapid PSA doubling time, and multiple cardiovascular and metabolic comorbidities, the expert faculty discuss how risk stratification and patient-specific factors influence treatment selection.
In this episode, “Preserving Quality of Life in Metastatic Castration-Sensitive Prostate Cancer,” the expert faculty explore how cognitive function, independence, and patient priorities influence treatment selection for metastatic castration-sensitive prostate cancer (mCSPC). Through the case of a 74-year-old man with low-volume metastatic disease, mild cognitive impairment, and a strong desire to maintain an active lifestyle, the panel examines the importance of treating the whole patient rather than focusing solely on disease characteristics.
Welcome back to another Urology Times Virtual Tumor Board series. In this episode titled “Navigating Comorbidities and Treatment Decisions in Metastatic Castration-Sensitive Prostate Cancer,” expert faculty discuss a patient with advanced prostate cancer whose management highlights the importance of individualized treatment decisions that extend beyond tumor characteristics alone.
"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Prostate cancer is the most prevalent non-cutaneous cancer diagnosed in men today, still accounting for a significant amount of morbidity and mortality in spite of increased screening efforts and advances in treatment.
